Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
The company’s renal denervation system has failed in a crucial late-stage trial, just as an earlier version did eight years ago.
Buying Abiomed for $17bn sharpens the group’s focus, somewhat unexpectedly, on cardiovascular tech.
The $2.6bn acquisition of The Binding Site is 2022’s biggest medtech deal, but investors are unmoved.